Stocks
Longeveron Sets August 2026 ELPIS II Readout, Adopts Asset-Light Model
Longeveron (LGVN) targets an August 2026 readout for its ELPIS II study, simultaneously shifting to an asset-light partnering model under new leadership....
#clinical trials 3 articles
Stocks
Vaxart Sets Early 2027 Efficacy Readout, Q2 Sentinel Data Release Imminent
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...
Stocks
AZN’s Imfinzi Combo Wins Late-Stage Liver Cancer Trial
AstraZeneca (AZN) announced a successful late-stage trial for its Imfinzi combination regimen in a subset of liver cancer patients, bolstering the company's...